Novel Antibody for Chronic Hives Brings Relief in Mid-Stage Trial

(MedPage Today) -- WASHINGTON -- Barzolvolimab, a first-in-class anti-KIT monoclonal antibody, reduced the severity of hives in adults with chronic spontaneous urticaria (CSU) who remained symptomatic on antihistamines, a randomized phase II...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news